Creso Pharma has launched three new CBD-based tea products in Switzerland under its Cannaqix brand, with other European markets, including Germany, earmarked for near-term expansion.
The company said the teas have been developed using new technology to optimise the CBD content in compliance with regulations and allow for a better taste.
After completing legal and regulatory due diligence, the teas can be legally marketed and sold throughout Switzerland, via Creso’s established 2,100-strong distribution network.
The company will also look to launch its new hemp teas in Germany, following a recent decision by the German Federal Court of Justice to annul previous charges against hemp tea sellers which had temporarily delayed the scheduled Q3 2020 rollout of Creso’s hemp tea products.
Upon successful rollout in Switzerland and Germany, Creso will explore the opportunity to expand into other European markets subject to due diligence of the legal framework in each.
Creso commercial and development director Gian Trepp said: “We are proud to have completed the finalisation of this ground-breaking technology for our new CBD tea products, which opens a number of new and globally applicable opportunities for Creso Pharma.
“The new products and formulation provide a very tasty CBD tea that will become a key component in the future production of Cannaqix lozenges.”